Abstract: Provided herein are compositions that comprise a) a first recombinant adeno-associated viral (rAAV) vector genome (vg) comprising a first expression cassette comprising a promoter operably linked to nucleic acid sequence comprising a 5? portion of an otoferlin gene, wherein the expression cassette is flanked by inverted terminal repeats (ITRs); and b) a second rAAV vector genome comprising a second expression cassette comprising a nucleic acid sequence comprising a 3? portion of an otoferlin gene, wherein the expression cassette is flanked by ITRs, wherein the composition comprises about 4.1E10-4.1E12 total vg or about 8.1E10-8.1E12 total vg, and the use of these compositions to treat hearing loss in a subject.

Abstract: This invention relates to drug conjugates useful for localized treatment of diseases or disorders of the middle ear and/or inner ear. Methods of treating diseases or disorders of the middle ear and/or inner ear, pharmaceutical compositions comprising the conjugates, and methods of inhibiting a Tropomyosin receptor kinase are also provided.

Abstract: This invention relates to drug conjugates useful for localized treatment of diseases or disorders of the middle ear and/or inner ear. Methods of treating diseases or disorders of the middle ear and/or inner ear, pharmaceutical compositions comprising the conjugates, and methods of inhibiting a Tropomyosin receptor kinase are also provided.

Abstract: This invention relates to drug conjugates useful for localized treatment of diseases or disorders of the middle ear and/or inner ear. Methods of treating diseases or disorders of the middle ear and/or inner ear, pharmaceutical compositions comprising the conjugates, and methods of inhibiting a Tropomyosin receptor kinase are also provided.

Abstract: The present disclosure provides compositions and methods for treating an auditory disease in a subject in need thereof comprising administering an effective amount of a gel-based precursor that includes an inner ear-specific therapeutic compound directly into the cochlea of the subject.

Abstract: This invention relates to drug conjugates useful for localized treatment of diseases or disorders of the middle ear and/or inner ear. Methods of treating diseases or disorders of the middle ear and/or inner ear, pharmaceutical compositions comprising the conjugates, and methods of inhibiting a Tropomyosin receptor kinase are also provided.

Abstract: The present disclosure provides compositions and methods for treating an auditory disease in a subject in need thereof comprising administering an effective amount of a gel-based precursor that includes an inner ear-specific therapeutic compound directly into the cochlea of the subject.

Abstract: An implantable drug delivery apparatus for delivering a drug into a bodily fluid in a body cavity of a patient over a period of time, which includes a hollow member that defines at least one lumen for facilitating a unidirectional recirculating flow of a therapeutic fluid through the lumen. The fluid can contain a bodily fluid, such as, for example, perilymph, and a drug. The apparatus also includes a pump, for example a single unidirectional pump, to control the flow rate of the therapeutic fluid through the hollow member, and an interface member in communication with at least one lumen of the hollow member. The device thus allows for the controlled delivery of the therapeutic fluid to a predetermined location in the bodily cavity of the patient, such as, for example, a cochlea of a human ear.

Abstract: An improved metallic lamp socket enclosure of the cap-and-shell type for incandescent lamps is disclosed. According to the invention, the cap portion of the unit is provided with integral means for attaching a ground wire for safety purposes. The invention may be applied to units as they are manufactured or to previously manufactured units.A tool for forming the grounding means, and for effecting the attachment of a ground wire thereto, is also described.